Recently, Loi, et al. reported that CD73 in tumor cells conferred the resistance to doxorubicin, through suppressing adaptive antitumor immune responses by activating high-affinity A2A adenosine receptors [110]. This evidence concerns the gene ADORA2A and neoplasm.